Search company, investor...

Xcel Pharmaceuticals

Founded Year



Acquired | Acquired

Total Raised




About Xcel Pharmaceuticals

Xcel Pharmaceuticals is a specialty pharmaceutical company focused on prescription products that treat disorders of the central nervous system. Xcel's portfolio includes four products that are sold within the U.S. and a late-stage clinical product candidate.

Headquarters Location

6363 Greenwich Drive Suite 100

San Diego, California, 92122,

United States


Missing: Xcel Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Xcel Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Xcel Pharmaceuticals News

Valeant Pharmaceuticals to Acquire Xcel Pharmaceuticals; Acquisition Expands Valeant's Neurology Franchise in North America; Adds Retigabine to Pipeline

Jan 10, 2017

February 02, 2005 06:00 AM Eastern Standard Time COSTA MESA, Calif.--( BUSINESS WIRE )--Feb. 2, 2005--Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has signed a definitive agreement to acquire Xcel Pharmaceuticals, a privately held specialty pharmaceutical company focused on neurology products in the United States. The transaction significantly expands Valeant's business in North America and enhances the company's neurology franchise through the acquisition of key products and a highly specialized neurology sales organization consisting of 94 professionals. The transaction also adds retigabine, a novel Phase 3 candidate in clinical development for the treatment of epilepsy, to Valeant's pipeline. Valeant plans to market retigabine in the United States and key foreign markets once the Phase 3 trials are completed, subject to regulatory approval. The transaction is valued at approximately $280 million plus expenses, which includes retirement of $44 million in Xcel Pharmaceuticals debt. Valeant will pay either $280 million in cash or a combination of $230 million in cash and $50 million in shares of its common stock. Pursuant to the terms of the merger agreement and subject to certain conditions therein, Valeant will pay all cash if it consummates an equity offering for the purpose of financing the acquisition. The transaction was unanimously approved by the boards of directors for both companies and is expected to close following the expiration or early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvement Act of 1976, as amended. Timothy C. Tyson, Valeant's President and Chief Executive Officer, said, "We are very excited to announce this strategically important acquisition. In addition to the immediate expansion opportunity that Xcel provides for our growing neurology franchise in the United States, the combined infrastructure of both companies can be further leveraged towards future product launches. The Xcel acquisition provides Valeant with access to an excellent marketed product portfolio and a pipeline product with significant market potential in the United States and in our key foreign markets." The Xcel transaction adds several marketed neurology products that include Diastat(R), the only product approved for treatment of acute repetitive epileptic seizures outside of a hospital setting, and Migranal(R), a nasal spray used for the treatment of acute migraine headaches. Total sales of Xcel's products in the nine months ended September 30, 2004 were $45.9 million. Upon closing of the transaction, Valeant's sales force in the United States will increase to approximately 200 representatives. The Xcel acquisition also adds retigabine, an important new compound, to Valeant's research and development pipeline. Retigabine is a Phase 3 clinical candidate in development for treating epilepsy that successfully completed an End-of-Phase 2 meeting with the Food and Drug Administration (FDA). The Phase 2 trials included more than 600 patients in several dose-ranging studies compared to placebo. The results of the key Phase 2 study indicate that the compound is potentially efficacious with a demonstrated reduction in monthly seizure rates of 23 to 35 percent as adjunctive therapy in patients with partial seizures. Response rates in the two higher doses were statistically significant compared to placebo (p less than 0.001). Valeant expects to initiate Phase 3 trials for retigabine in the next few months. Assuming successful completion of the Phase 3 trials and approval by the FDA, Valeant expects to launch retigabine in early 2009. The Xcel transaction is expected to be modestly accretive to earnings in 2005, excluding the impact of acquired in-process research and development, currently estimated to be $120 million. The company expects to incur additional research and development expenses for retigabine, including the assumption of certain milestone payments, which would make the transaction dilutive for years after 2005, until the anticipated launch of retigabine in 2009. Valeant will provide additional information on the transaction, including its impact on expectations for financial metric performance in 2005, when it reports its fourth quarter financial results on February 24, 2005. Bear, Stearns & Co. Inc. acted as financial advisor to Valeant in the transaction. Conference Call and Webcast: Valeant will host a conference call today, February 2, 2005, at 8:30 AM EST (5:30 AM PST) to discuss the acquisition. To participate, please dial (877) 295-5743, confirmation code 3829765. International callers should dial (706) 679-0845. Valeant will also webcast the call live over the Internet in the investor relations section of the company's Web site at . A replay will be available approximately two hours following the conclusion of the conference call through February 9, 2005, and can be accessed by dialing (800) 642-1687, confirmation code 3829765. IMPORTANT SAFETY INFORMATION: In pivotal trials with Diastat (diazepam rectal gel) the most frequent adverse event reported was somnolence (23%). Less frequent adverse events reported were dizziness, headache pain, abdominal pain, nervousness, vasodilation, diarrhea, ataxia, euphoria, incoordination, asthma, rhinitis, and rash (2-5%). The most commonly reported adverse events in clinical trials for MIGRANAL Nasal Spray were rhinitis, altered sense of taste, application site reactions, dizziness, nausea and vomiting. Adverse events associated with discontinuation were rhinitis, dizziness, facial edema, cold sweats, accidental trauma, depression, somnolence, allergy, vomiting, hypotension, and paresthesia. Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. MIGRANAL Nasal Spray should not be given to patients with ischemic heart disease or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina. MIGRANAL Nasal Spray also should not be given to patients with uncontrolled hypertension, patients who have used 5-HT(1) agonists, ergotamine-containing or ergot-type medications or methysergide within the last 24 hours, or patients with hemiplegic or basilar migraine. MIGRANAL Nasal Spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. MIGRANAL Nasal Spray should not be administered to pregnant women or nursing mothers. Serious cardiac events, including some that have been fatal, have occurred following use of DHE 45 but are extremely rare. During clinical studies and the foreign postmarketing experience with MIGRANAL Nasal Spray, there have been no fatalities due to cardiac events. Retigabine has not been proven safe or effective in the diagnosis, treatment, or prevention of any disease or illness, or approved by the FDA or any corresponding foreign regulatory agency. Until such time as Valeant receives approval to market retigabine, it may not be sold or offered for sale in the United States or abroad. About Valeant Valeant Pharmaceuticals International (NYSE:VRX) is a global, publicly traded, research-based specialty pharmaceutical company that discovers, develops, manufactures and markets a broad range of pharmaceutical products. More information about Valeant can be found at . About Xcel Xcel Pharmaceuticals, Inc., based in San Diego, California, is a specialty pharmaceutical company focused on prescription products that treat disorders of the central nervous system. Xcel's portfolio includes four products that are sold within the U.S. and a late-stage clinical product candidate. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of the federal securities laws relating to expectations, plans or prospects for Valeant Pharmaceuticals, including our ability to successfully close the transaction and integrate Xcel's operations into those of Valeant, obtain approval of retigabine and other pipeline candidates within the company's estimated timeline or at all, and successfully expand the company's neurology business. These statements are based upon the current expectations and beliefs of Valeant Pharmaceuticals' management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond Valeant Pharmaceuticals' control, adverse events that would require clinical trials to be prematurely terminated, clinical results that indicate continuing clinical and commercial pursuit of retigabine is not advisable, the fact that Phase 2 clinical trial results are not always indicative of those seen in Phase 3 clinical trials, the possibility of entry of generic competition for Diastat, and the risk factors and other cautionary statements discussed in Valeant Pharmaceuticals' filings with the U.S. Securities and Exchange Commission. Contacts Jeff Misakian, 714-545-0100 ext. 3309 Contacts Jeff Misakian, 714-545-0100 ext. 3309 Site Navigation

Xcel Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Xcel Pharmaceuticals founded?

    Xcel Pharmaceuticals was founded in 2001.

  • Where is Xcel Pharmaceuticals's headquarters?

    Xcel Pharmaceuticals's headquarters is located at 6363 Greenwich Drive, San Diego.

  • What is Xcel Pharmaceuticals's latest funding round?

    Xcel Pharmaceuticals's latest funding round is Acquired.

  • How much did Xcel Pharmaceuticals raise?

    Xcel Pharmaceuticals raised a total of $118.5M.

  • Who are the investors of Xcel Pharmaceuticals?

    Investors of Xcel Pharmaceuticals include Bausch Health, Greenspring Associates, Ferrer Freeman & Company, New Enterprise Associates, Domain Associates and 3 more.

  • Who are Xcel Pharmaceuticals's competitors?

    Competitors of Xcel Pharmaceuticals include Numares, Intas Pharmaceuticals, ISTA Pharmaceuticals, VIA Pharmaceuticals, Qualitest Pharmaceuticals and 11 more.

Compare Xcel Pharmaceuticals to Competitors


Phylogix is an early-stage pharmaceutical company developing chemoprotectant compounds.

Nimura Genetic Solutions

Isolating diverse creatures including species indegenous to rainforests in Malaysia, exploring new compounds which lead development of new medicine conforming to CBD and building a predominant bio-resource collection, NGS will contribute to health and progress of bioindustries in international community.

Synapsin Pharmaceuticals

SYNAPSIN is developing therapeutic strategies for the treatmentand prevention ofneurodegenerative disorders such as Alzheimer's disease (AD),Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and spinal cord injury.


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Meditrina Pharmaceuticals

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs.

Intranasal Therapeutics

Intranasal Therapeutics, founded in 1998 by Edwin Cohen, founder and former Chairman and CEO of Barr Laboratories, Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products, with a particular focus on drugs treating pain and disorders related to the central nervous system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.